These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 35074728)

  • 1. Immune response to SARS-CoV-2 variants: A focus on severity, susceptibility, and preexisting immunity.
    Alefishat E; Jelinek HF; Mousa M; Tay GK; Alsafar HS
    J Infect Public Health; 2022 Feb; 15(2):277-288. PubMed ID: 35074728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants.
    Noor R
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36423150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Variants of Concern.
    Choi JY; Smith DM
    Yonsei Med J; 2021 Nov; 62(11):961-968. PubMed ID: 34672129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity.
    Loos C; Atyeo C; Fischinger S; Burke J; Slein MD; Streeck H; Lauffenburger D; Ryan ET; Charles RC; Alter G
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32878931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 Variant Delta Potently Suppresses Innate Immune Response and Evades Interferon-Activated Antiviral Responses in Human Colon Epithelial Cells.
    Tandel D; Sah V; Singh NK; Potharaju PS; Gupta D; Shrivastava S; Sowpati DT; Harshan KH
    Microbiol Spectr; 2022 Oct; 10(5):e0160422. PubMed ID: 36073824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Immune Response to SARS-CoV-2 and Variants of Concern.
    Torbati E; Krause KL; Ussher JE
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies.
    Sánchez-Zuno GA; Matuz-Flores MG; González-Estevez G; Nicoletti F; Turrubiates-Hernández FJ; Mangano K; Muñoz-Valle JF
    Int J Immunopathol Pharmacol; 2021; 35():20587384211050199. PubMed ID: 34632844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.
    Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ
    Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Observations and Perspectives on Adaptive Immunity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
    Dan J; da Silva Antunes R; Grifoni A; Weiskopf D; Crotty S; Sette A
    Clin Infect Dis; 2022 Aug; 75(Suppl 1):S24-S29. PubMed ID: 35441229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interaction between SARS-CoV-2 and Host Innate Immunity].
    Duan XQ; Xie H; Chen LM
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2022 Jan; 53(1):1-6. PubMed ID: 35048592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innate and Adaptive Immune Responses in the Upper Respiratory Tract and the Infectivity of SARS-CoV-2.
    Ramasamy R
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 Spike-Specific CD4+ T Cell Response Is Conserved Against Variants of Concern, Including Omicron.
    Mazzoni A; Vanni A; Spinicci M; Capone M; Lamacchia G; Salvati L; Coppi M; Antonelli A; Carnasciali A; Farahvachi P; Giovacchini N; Aiezza N; Malentacchi F; Zammarchi L; Liotta F; Rossolini GM; Bartoloni A; Cosmi L; Maggi L; Annunziato F
    Front Immunol; 2022; 13():801431. PubMed ID: 35154116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunopathogenesis and immunobiology of SARS-CoV-2.
    Rabaan AA; Al-Ahmed SH; Al Mutair A; Alhumaid S; Sule AA; Tirupathi R; Fawzy M; Muhammad J; Khan A; Hasan A; Shrestha DB; Sah R; Dhawan M; Tiwari R; Bilal M; Ahmad T; Dhama K
    Infez Med; 2021 Jun; 29(2):167-180. PubMed ID: 34061781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic and transcriptomic differences of emerging SARS-CoV-2 variants in the Syrian golden hamster model.
    O'Donnell KL; Pinski AN; Clancy CS; Gourdine T; Shifflett K; Fletcher P; Messaoudi I; Marzi A
    EBioMedicine; 2021 Nov; 73():103675. PubMed ID: 34758415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The Challenges of Vaccine Development Against Betacoronaviruses: Antibody Dependent Enhancement and Sendai Virus as a Possible Vaccine Vector].
    Zaichuk TA; Nechipurenko YD; Adzhubey AA; Onikienko SB; Chereshnev VA; Zainutdinov SS; Kochneva GV; Netesov SV; Matveeva OV
    Mol Biol (Mosk); 2020; 54(6):922-938. PubMed ID: 33276356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.